ACER THERAPEUTICS INC. Increase (Decrease) in Other Current Liabilities
ACER THERAPEUTICS INC. reported Increase (Decrease) in Other Current Liabilities of -$9.27 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2023-11-20
- ACER THERAPEUTICS INC. increase (decrease) in other current liabilities for the quarter ending 2022-12-31 was -$24.27K, a 1372.06% decline year-over-year.
- ACER THERAPEUTICS INC. increase (decrease) in other current liabilities for the quarter ending 2022-09-30 was -$50.57K.
- ACER THERAPEUTICS INC. increase (decrease) in other current liabilities for the quarter ending 2022-06-30 was -$757.44K.
- ACER THERAPEUTICS INC. increase (decrease) in other current liabilities for the quarter ending 2022-03-31 was -$8.43M, a 185.60% decline year-over-year.
- ACER THERAPEUTICS INC. increase (decrease) in other current liabilities for fiscal 2022 was -$9.27M, a 200.03% decline from fiscal 2021.
- ACER THERAPEUTICS INC. increase (decrease) in other current liabilities for fiscal 2021 was $9.26M, a 162977.83% increase from fiscal 2020.
- ACER THERAPEUTICS INC. increase (decrease) in other current liabilities for fiscal 2020 was $5.68K.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$24.27K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$74.84K derived: sum of 2 quarters · filed 2023-11-20 | -$832.28K derived: sum of 3 quarters · filed 2023-11-20 | -$9.27M 10-K · filed 2023-03-27 |
| 2022-09-30 | -$50.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-20 | -$808.01K derived: sum of 2 quarters · filed 2023-11-20 | -$9.24M 10-Q · filed 2023-11-20 | -$9.24M derived: sum of 4 quarters · filed 2023-11-20 |
| 2022-06-30 | -$757.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$9.19M 10-Q · filed 2023-08-14 | -$9.19M derived: sum of 3 quarters · filed 2023-08-14 | -$9.33M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$8.43M 10-Q · filed 2023-05-15 | -$8.43M derived: sum of 2 quarters · filed 2023-05-15 | -$8.57M derived: sum of 3 quarters · filed 2023-05-15 | -$9.02M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $1.91K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$137.89K derived: sum of 2 quarters · filed 2023-03-27 | -$589.70K derived: sum of 3 quarters · filed 2023-03-27 | $9.26M 10-K · filed 2023-03-27 |
| 2021-09-30 | -$139.79K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2022-11-14 | -$591.61K derived: sum of 2 quarters · filed 2022-11-14 | $9.26M 10-Q · filed 2022-11-14 | $9.26M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$451.82K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2022-11-14 | $9.40M 10-Q/A · filed 2022-11-14 | $9.40M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-03-31 | $9.85M 10-Q · filed 2022-05-16 | $9.85M derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | -$2.04K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $5.68K 10-K · filed 2022-03-02 | ||
| 2020-09-30 | $7.72K 10-Q · filed 2021-11-19 | |||
| 2020-03-31 | -$773.27K 10-Q/A · filed 2021-11-19 |